表 1.
CADM与DM的临床表现及实验室指标比较
Comparison of clinical manifestations and laboratory parameters between CADM and DM
| Items | CADM (n=106) | DM (n=158) | F/χ2 | P |
| Values displayed as n(%), x±s, or median (P25, P75) according to their features of distribution. ILD，interstitial lung disease; CADM，clinically amyopathic dermatomyositis; DM，dermatomyositis; CTD，connective tissue disease; TAA，tumor associated antigens; CEA，carcinoembryonic antigen; AFP，alpha-fetoprotein; CYFRA21-1，cytokeratin-19 fragment; NES，neuron specific enolase; CA19-9，Carbohydrate antigen 19-9; RF，rheumatoid factors; ANA，antinuclear antibodies. *The data of RF and ANA was missing in four patients in CADM and two patients in DM. | ||||
| Age/years, x±s | 50.47±12.44 | 51.63±13.85 | 0.484 | 0.487 |
| Gender，female :male (%female) | 82 :24 (77.4) | 109 :49 (69.0) | 2.222 | 0.136 |
| Age of onset/years, x±s | 48.84±13.07 | 48.92±14.79 | 0.001 | 0.969 |
| Cutaneous manifestation | ||||
| Gottron's sign/papule, n(%) | 85 (80.2) | 115 (72.8) | 1.894 | 0.169 |
| Mechanic's hands, n(%) | 41 (38.7) | 56 (35.4) | 0.286 | 0.593 |
| Heliotrope eruption, n(%) | 59 (55.7) | 82 (51.9) | 0.361 | 0.548 |
| V shawl neck sign, n(%) | 59 (55.7) | 92 (58.2) | 0.171 | 0.679 |
| Skin ulceration, n(%) | 13 (12.3) | 17 (10.8) | 0.143 | 0.706 |
| Perionychia erythma, n(%) | 21 (19.8) | 35 (22.2) | 0.208 | 0.648 |
| Skin calcinosis, n(%) | 7 (6.6) | 8 (5.1) | 0.281 | 0.596 |
| Pulmonary involvement | ||||
| ILD, n(%) | 84 (79.2) | 131 (82.9) | 0.564 | 0.453 |
| Acute, n(%) | 49 (58.3) | 34 (26.0) | 22.640 | < 0.001 |
| Asymptomatic, n(%) | 17 (20.2) | 43 (32.8) | 4.030 | 0.045 |
| ILD onset before CADM diagnosed, n(%) | 22 (20.7) | 12 (7.6) | 9.792 | 0.002 |
| Systemic symptoms | ||||
| Noninfectious fever, n(%) | 41 (38.7) | 56 (35.4) | 0.286 | 0.593 |
| Arthralgia, n(%) | 56 (52.8) | 65 (41.1) | 3.493 | 0.062 |
| Raynaud phenomenon, n(%) | 12 (11.3) | 22 (13.9) | 0.383 | 0.536 |
| Splenomegaly, n(%) | 11 (10.4) | 10 (6.3) | 1.383 | 0.240 |
| Weight loss, n(%) | 38 (35.8) | 44 (27.8) | 1.897 | 0.168 |
| Accompanied CTD, n(%) | 20 (18.9) | 31 (19.6) | 0.023 | 0.879 |
| Accompanied malignancy, n(%) | 5 (4.7) | 14 (8.9) | 1.631 | 0.202 |
| Serum TAAs | ||||
| CEA/(μg/L), M(P25, P75) | 2.89 (1.76, 5.27) | 2.00 (1.10, 4.03) | 2.750 | 0.006 |
| AFP/(μg/L), M(P25, P75) | 2.45 (1.89, 3.17) | 2.45 (1.78, 3.46) | 0.297 | 0.767 |
| CA19-9/(U/mL), M(P25, P75) | 11.81 (4.97, 16.53) | 9.92 (5.78, 18.87) | 0.471 | 0.638 |
| CYFRA21-1/(μg/L), M(P25, P75) | 3.38 (2.05, 5.49) | 3.06 (2.36, 4.81) | 0.260 | 0.795 |
| NSE/(μg/L), M(P25, P75) | 14.08 (11.15, 17.20) | 16.20 (12.39, 23.47) | 2.848 | 0.004 |
| Immunological parameters | ||||
| RF positive, n(%)* | 11 (10.8) | 32 (20.5) | 4.203 | 0.040 |
| ANA (≥1 :80)，n(%)* | 36 (35.3) | 78 (50.0) | 6.538 | 0.011 |